4PVT image
Entry Detail
PDB ID:
4PVT
Title:
Crystal Structure of VIM-2 metallo-beta-lactamase in complex with ML302F
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2014-03-18
Release Date:
2014-11-19
Method Details:
Experimental Method:
Resolution:
2.00 Å
R-Value Free:
0.21
R-Value Work:
0.16
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Beta-lactamase class B VIM-2
Chain IDs:A, B
Chain Length:242
Number of Molecules:2
Biological Source:Pseudomonas aeruginosa
Primary Citation
Rhodanine hydrolysis leads to potent thioenolate mediated metallo-beta-lactamase inhibition.
Nat.Chem. 6 1084 1090 (2014)
PMID: 25411887 DOI: 10.1038/nchem.2110

Abstact

The use of β-lactam antibiotics is compromised by resistance, which is provided by β-lactamases belonging to both metallo (MBL)- and serine (SBL)-β-lactamase subfamilies. The rhodanines are one of very few compound classes that inhibit penicillin-binding proteins (PBPs), SBLs and, as recently reported, MBLs. Here, we describe crystallographic analyses of the mechanism of inhibition of the clinically relevant VIM-2 MBL by a rhodanine, which reveal that the rhodanine ring undergoes hydrolysis to give a thioenolate. The thioenolate is found to bind via di-zinc chelation, mimicking the binding of intermediates in β-lactam hydrolysis. Crystallization of VIM-2 in the presence of the intact rhodanine led to observation of a ternary complex of MBL, a thioenolate fragment and rhodanine. The crystallographic observations are supported by kinetic and biophysical studies, including (19)F NMR analyses, which reveal the rhodanine-derived thioenolate to be a potent broad-spectrum MBL inhibitor and a lead structure for the development of new types of clinically useful MBL inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures